Resources

Specialty Pharmacy Overview

Frier Levitt has been at the forefront of fighting against PBM- imposed DIR Fees. Certain types of pharmacies, including specialty pharmacies and dispensing…

Download Specialty Pharmacy Overview PDF

Topics

Pharmacy Law

Life Sciences & Pharmacy

Articles

09/01/2026

Manufacturers Cannot Adopt 340B Rebate Models Without HRSA Approval

News

08/24/2026

Edgar Asebey Featured in Axios: “Unapproved obesity drug spawns a black market frenzy”

Articles

08/21/2026

Types of State Board of Pharmacy Inspections and How to Prepare for Them

Events

09/22/2026 – 09/25/2026

Jesse Dresser Speaks at NASP’s inSPire 2026

Articles

08/18/2026

Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook

Articles

08/17/2026

Arkansas Suspends Enforcement of Act 630: What the Limited Distribution Network Ruling Means for Pharmacies

News

08/14/2026

Edgar Asebey Featured in The Capitol Forum: “A Closer Look at FDA’s Next Steps Following Advisory Committee’s Recommendation to Legalize Compounding for Wellness Peptides”

Articles

08/13/2026

Pharmacy-to-Pharmacy Inventory Transfers: Navigating PBM Audit Scrutiny Under the DSCSA

Articles

08/13/2026

FTC’s Caremark Settlement: What It Means for Pharmacies, PSAOs, and Wholesalers

Articles

08/11/2026

Cut Off Without Warning: What to Do When Mallinckrodt Restricts Your Pharmacy’s Controlled Substance Purchases

Webinars

08/20/2026

The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models

Articles

08/06/2026

What Is a State Board of Pharmacy and Why Does It Inspect You?

Articles

08/05/2026

Florida Attorney General Issues Civil Investigative Demand to CVS Health and Caremark Over Alleged Anticompetitive Practices

Articles

08/04/2026

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 2: Strategic Implications and Compliance Roadmap

News

08/03/2026

Jesse Dresser Featured in NPR: “What would it take to get peptides on the shelf?”

News

07/31/2026

Edgar Asebey Featured in CNN Health: “FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next”

News

07/31/2026

Edgar Asebey Quoted in Mezha: “FDA panel backs compounding access for six peptides, approval still pending”

News

07/30/2026

Jesse Dresser and Edgar Asebey Quoted in Peptides Business Wire: “Is legal access to peptides inevitable?”

News

07/28/2026

Edgar Asebey Quoted in WP Intelligence Health Brief: “What’s next for the peptide industry after advisory committee recommendations”

Articles

07/28/2026

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 1: PBM Transparency and New Compensation Rules

Call Us Now

Specialty Pharmacy Overview

Related Insights

Manufacturers Cannot Adopt 340B Rebate Models Without HRSA Approval

Edgar Asebey Featured in Axios: “Unapproved obesity drug spawns a black market frenzy”

Types of State Board of Pharmacy Inspections and How to Prepare for Them

Jesse Dresser Speaks at NASP’s inSPire 2026

Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook

Arkansas Suspends Enforcement of Act 630: What the Limited Distribution Network Ruling Means for Pharmacies

Edgar Asebey Featured in The Capitol Forum: “A Closer Look at FDA’s Next Steps Following Advisory Committee’s Recommendation to Legalize Compounding for Wellness Peptides”

Pharmacy-to-Pharmacy Inventory Transfers: Navigating PBM Audit Scrutiny Under the DSCSA

FTC’s Caremark Settlement: What It Means for Pharmacies, PSAOs, and Wholesalers

Cut Off Without Warning: What to Do When Mallinckrodt Restricts Your Pharmacy’s Controlled Substance Purchases

The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models

What Is a State Board of Pharmacy and Why Does It Inspect You?

Florida Attorney General Issues Civil Investigative Demand to CVS Health and Caremark Over Alleged Anticompetitive Practices

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 2: Strategic Implications and Compliance Roadmap

Jesse Dresser Featured in NPR: “What would it take to get peptides on the shelf?”

Edgar Asebey Featured in CNN Health: “FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next”

Edgar Asebey Quoted in Mezha: “FDA panel backs compounding access for six peptides, approval still pending”

Jesse Dresser and Edgar Asebey Quoted in Peptides Business Wire: “Is legal access to peptides inevitable?”

Edgar Asebey Quoted in WP Intelligence Health Brief: “What’s next for the peptide industry after advisory committee recommendations”

CAA 2026: What Pharmaceutical Manufacturers Need to Know – Part 1: PBM Transparency and New Compensation Rules